Adsorption kinetics of high mobility group box 1 protein in a polyacrylonitrile hemofiltration membrane.
adsorption mechanism
hemofiltration
high mobility group box 1 protein
immunoelectron microscopy
polyacrylonitrile membrane
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
10
12
2019
revised:
17
03
2020
accepted:
19
03
2020
pubmed:
28
3
2020
medline:
8
10
2021
entrez:
28
3
2020
Statut:
ppublish
Résumé
The high mobility group box 1 protein (HMGB1) is recognized as a prototypical endogenous danger cytokine in sepsis. We previously reported that a polyacrylonitrile (AN69ST) membrane rapidly adsorbed HMGB1. Herein, an in vitro hemofiltration system was designed to assess the HMGB1 adsorption capacity, adsorption sites, and adsorption mechanism of the AN69ST membrane. HMGB1 was repeatedly added seven times during hemofiltration. A rapid decrease in circulating HMGB1 was observed after every addition with no sign of saturation. Presence of HMGB1 on the filter membrane was observed on both membrane surfaces and within the bulk layer using a high concentration of HMGB1 by immunoelectron microscopy. We hypothesized that the addition of heparin to the membrane surface or filtration rate would contribute to the adsorption mechanism. We could not measure the influence of heparin and filtration. Although the membrane was too large to saturate under the μg/mL HMGB1 conditions, our results show that the AN69ST membrane has a robust absorption capacity that could be used to treat sepsis.
Identifiants
pubmed: 32216030
doi: 10.1111/1744-9987.13489
doi:
Substances chimiques
Acrylic Resins
0
HMGB1 Protein
0
Membranes, Artificial
0
polyacrylonitrile
25014-41-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-72Subventions
Organisme : Scholarship donations from BAXTER
ID : GJ010165
Organisme : Scholarship donations from BAXTER
ID : GJ011928
Organisme : Scholarship donations from BAXTER
ID : GJ013226
Informations de copyright
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-251.
Yang H, Wang H, Chavan S, Andersson U. High mobility group box protein 1 (HMGB1): The prototypical endogenous danger molecule. Mol Med. 2015;21(Suppl 1):S6-S12.
Deng M, Tang Y, Li W, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis. Immunity. 2018;49:740-753.
Venereau E, De Leo F, Mezzapelle R, Careccia G, Musco G, Bianchi ME. HMGB1 as biomarker and drug target. Pharm Res. 2016;111:534-544.
Yumoto M, Nishida O, Moriyama K, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial. 2011;15:385-393.
Hara Y, Shimomura Y, Nakamura T, et al. Novel blood purification system for regulating excessive immune reactions in severe sepsis and septic shock: An ex vivo pilot study. Ther Apher Dial. 2015;19:308-315.
Malard B, Florens N, Lambert C, Julliard L. Adsorption as a contributor for inflammatory mediators removal by different hemofiltration membranes: A pilot study. Artif Organs. 2017;41:545-555.
Thomas M, Moriyama K, Ledebo I. AN69: Evolution of the world's first high permeability membrane. Contrib Nephrol. 2011;173:119-129.
Honoré PM, Jacobs R, Joannes-Boyau O, et al. Newly designed CRRT membranes for sepsis and SIRS-A pragmatic approach for bedside intensivists summarizing the more recent advances: A systematic structured review. ASAIO J. 2013;59:99-106.
Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I. New high mobility group box 1 assay system. Clin Chim Acta. 2006;372:173-178.
Moriyama K, Soejima Y. Continuous hemodiafiltration using PMMA membrane: Clinical efficacy and its mechanisms. Contrib Nephrol. 1999;125:222-232.
Hirayama T, Nosaka N, Okawa Y, et al. AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: A retrospective study. J Intensive Care. 2017;5:46.
Ronco C, Ricci Z, De Backer D, et al. Renal replacement therapy in acute kidney injury: Controversy and consensus. Crit Care. 2015;19:p1.
Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: The promises and the pitfalls. Crit Care. 2018;22:262.
Hirasawa H, Oda S, Nakamura M, Watanabe E, Shiga H, Matsuda K. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis. Blood Purif. 2012;34:164-170.
Tumlin JA, Galphin CM, Tolwani AJ, et al. A multi-center, randomized, controlled, pivotal study to assess the safety and efficacy of a selective Cytopheretic device in patients with acute kidney injury. PLoS One. 2015;10:e0132482.
Hawchar F, László I, Öveges N, Trásy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172-178.
Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open. 2014;4:e003536.
Rimmelé T, Kaynar AM, McLaughlin JN, et al. Leukocyte capture and modulation of cell-mediated immunity during human sepsis: An ex vivo study. Crit Care. 2013;17:R59.
Honoré PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28:3581-3587.
Nishida O, Nakamura T, Kuriyama N, et al. Sustained high efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) in the treatment of patients with severe sepsis. Contrib Nephrol. 2011;173:172-181.
Shiga H, Hirasawa H, Nishida O, et al. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: A preliminary report. Blood Purif. 2014;38:211-218.
Doi K, Iwagami M, Yoshida E, Marshall MR. Associations of polyethylenimine-coated AN69ST membrane in continuous renal replacement therapy with the intensive care outcomes: Observations from a claims database from Japan. Blood Purif. 2017;44:184-192.
Chanard J, Lavaud S, Paris B, et al. Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. preclinical studies. ASAIO J. 2005;51:342-347.
Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J, Rauvala H. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem. 1991;266:16722-16729.
Rimmelé T, Kellum JA. High-volume hemofiltration in the intensive care unit: A blood purification therapy. Anesthesiology. 2012;116:1377-1387.